VRT106

AXP000128.1 · Oncolytic virus

Platform
oncolytic alphavirus M1 (recombinant)
Originator
Sun Yat-sen University
Sponsor
Guangzhou Virotech Pharmaceutical

Names

NameTypeSource
VRT106preferred name, codecurator, ctgov
oncolytic virus M1 ambiguoussynonymctgov

Virus

Role
Oncolytic
Family
Togaviridae
Virus
Getah virus (NCBI Taxonomy 59300)
Strain
oncolytic virus M1 (VRT106)
Replication
replicating
Modifications
recombinant M1 alphavirus; details not disclosed
Route
intratumoral
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (9)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07589244A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCCRecruitingPhase 2/32026-05-132028-12-3166HCC
NCT07589257A Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midline Glioma / Diffuse Intrinsic Pontine GliomaRecruitingPhase 22026-05-072028-06-3010Diffuse Intrinsic Pontine Glioma; Diffuse Midline Glioma, H3 K27M-Mutant
NCT07486310Evaluation of Pressurized Intraperitoneal Aerosol Chemotherapy With VRT106 Versus PIPAC in Patients With Advanced Gastric Cancer and PeritonealMetastasis: A Prospective, Multicenter, Open-Label, Randomized Controlled TrialNot yet recruitingPhase 22026-03-012028-03-0130Advanced Gastric Cancer
NCT07093814A Study of VRT106 for Injection in Patients With Recurrent/Progressive GlioblastomaRecruitingPhase 1/22025-09-022028-12-3142Glioblastoma
NCT06826313A Study of Intravenous VRT106 for Locally Advanced or Metastatic Solid TumorsRecruitingPhase 12025-03-192028-12-3012Solid Tumors
NCT06758544A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Resectable Pancreatic CancerRecruitingPhase 1/22025-03-172026-09-3018Pancreatic Cancer
NCT06866977A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Advanced Pancreatic CancerNot yet recruitingPhase 1/22025-03-122025-10-3110Pancreatic Cancer
NCT06368921A Study of Recombinant Oncolytic Virus M1(VRT106) in Patients With Solid TumorsRecruitingPhase 12024-06-192027-0930Solid Tumor
NCT04665362IIT Study of M1-c6v1 Combined With SHR-1210 and Apatinib in Patients With HCCUnknownPhase 12021-01-252022-06-0110Advanced/Metastatic Hepatocellular Carcinoma

Recent changes

No changes recorded in its trials yet.

Clinical papers

No confirmed clinical papers yet.

Other papers

Preclinical studies, reviews and other papers that name it.

No confirmed other papers yet.

Unconfirmed matches (29)

Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.

PubMedTitleJournalYearLinked by
PMID 41781696Oncolytic virus M1 reinvigorates CD8+ T-cell immunity against glioblastoma through B-cell-dependent antigen cross-presentation in the spleen.Cellular & molecular immunology2026name in title: oncolytic virus M1
PMID 41903911Investigating oncolytic virus M1-Associated vesicles using 3D electron microscopy.Journal of structural biology2026name in title: oncolytic virus M1
PMID 41964220Identification of YBX1 as an essential host RNA-binding protein governing tumor-selective replication of oncolytic virus M1.Molecular therapy : the journal of the American Society of Gene Therapy2026name in title: oncolytic virus M1
PMID 42178397Sirolimus potentiates oncolytic Virus M1 efficacy through tumor-selective augmentation of viral replication.Acta pharmacologica Sinica2026name in title: oncolytic virus M1
PMID 42369044Clinical dose of enoxaparin enhances oncolytic virus M1 infection and antitumor efficacy in human bladder cancer.iScience2026name in title: oncolytic virus M1
PMID 39866243circ-1584 selectively promotes the antitumor activity of the oncolytic virus M1 on pancreatic cancer.Molecular therapy. Oncology2025name in title: oncolytic virus M1
PMID 41053536Identification of TPRA1 as a Novel Receptor and Predictive Biomarker for Oncolytic Virus M1.Advanced science (Weinheim, Baden-Wurttemberg, Germany)2025name in title: oncolytic virus M1
PMID 41136390Retraction Note: DNA-PK inhibition synergizes with oncolytic virus M1 by inhibiting antiviral response and potentiating DNA damage.Nature communications2025name in title: oncolytic virus M1
PMID 41238218TAMs-mediated resistance to oncolytic virus M1 in solid tumors.Journal for immunotherapy of cancer2025name in title: oncolytic virus M1
PMID 38817541Enhancing antitumor efficacy of oncolytic virus M1 via albendazole-sustained CD8+ T cell activation.Molecular therapy. Oncology2024name in title: oncolytic virus M1
PMID 38828147Pharmacokinetic enhancement of oncolytic virus M1 by inhibiting JAK‒STAT pathway.Acta pharmaceutica Sinica. B2024name in title: oncolytic virus M1
PMID 37820722Oncolytic virus M1 functions as a bifunctional checkpoint inhibitor to enhance the antitumor activity of DC vaccine.Cell reports. Medicine2023name in title: oncolytic virus M1
PMID 37864032STT3A-mediated viral N-glycosylation underlies the tumor selectivity of oncolytic virus M1.Oncogene2023name in title: oncolytic virus M1
PMID 35393389Identification of the receptor of oncolytic virus M1 as a therapeutic predictor for multiple solid tumors.Signal transduction and targeted therapy2022name in title: oncolytic virus M1
PMID 35552024Overcoming resistance to oncolytic virus M1 by targeting PI3K-γ in tumor-associated myeloid cells.Molecular therapy : the journal of the American Society of Gene Therapy2022name in title: oncolytic virus M1
PMID 33338804Suppression of CCDC6 sensitizes tumor to oncolytic virus M1.Neoplasia (New York, N.Y.)2021name in title: oncolytic virus M1
PMID 34086978Cytotoxic T lymphocyte-associated protein 4 antibody aggrandizes antitumor immune response of oncolytic virus M1 via targeting regulatory T cells.International journal of cancer2021name in title: oncolytic virus M1
PMID 32829653Systematic Characterization of the Biodistribution of the Oncolytic Virus M1.Human gene therapy2020name in title: oncolytic virus M1
PMID 33037696Tumors driven by RAS signaling harbor a natural vulnerability to oncolytic virus M1.Molecular oncology2020name in title: oncolytic virus M1
PMID 33311488Intravenous injection of the oncolytic virus M1 awakens antitumor T cells and overcomes resistance to checkpoint blockade.Cell death & disease2020name in title: oncolytic virus M1
PMID 30604617Liposome Encapsulation of Oncolytic Virus M1 To Reduce Immunogenicity and Immune Clearance in Vivo.Molecular pharmaceutics2019name in title: oncolytic virus M1
PMID 29263275Deficiency of the IRE1α-Autophagy Axis Enhances the Antitumor Effects of the Oncolytic Virus M1.Journal of virology2018name in title: oncolytic virus M1
PMID 29449555Intravenous injections of the oncolytic virus M1 as a novel therapy for muscle-invasive bladder cancer.Cell death & disease2018name in title: oncolytic virus M1
PMID 30337542DNA-PK inhibition synergizes with oncolytic virus M1 by inhibiting antiviral response and potentiating DNA damage.Nature communications2018name in title: oncolytic virus M1
PMID 28445966Interferon alpha antagonizes the anti-hepatoma activity of the oncolytic virus M1 by stimulating anti-viral immunity.Oncotarget2017name in title: oncolytic virus M1
PMID 28607091Selective replication of oncolytic virus M1 results in a bystander killing effect that is potentiated by Smac mimetics.Proceedings of the National Academy of Sciences of the United States of America2017name in title: oncolytic virus M1
PMID 28835517Targeting VCP enhances anticancer activity of oncolytic virus M1 in hepatocellular carcinoma.Science translational medicine2017name in title: oncolytic virus M1
PMID 26373347Activation of Cyclic Adenosine Monophosphate Pathway Increases the Sensitivity of Cancer Cells to the Oncolytic Virus M1.Molecular therapy : the journal of the American Society of Gene Therapy2016name in title: oncolytic virus M1
PMID 27296553Naturally Existing Oncolytic Virus M1 Is Nonpathogenic for the Nonhuman Primates After Multiple Rounds of Repeated Intravenous Injections.Human gene therapy2016name in title: oncolytic virus M1

Notes

Recombinant oncolytic virus M1, a Getah-like alphavirus; phase 1 of intratumoral injection in advanced solid tumours (NCT06368921). Taxonomy assigned to Getah virus is the curator's best match and is not confirmed by the sponsor.

How to cite

VRT106 (AXP000128.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000128.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.